Loading
NASDAQHealthcareBiotechnology
Latest quote
$7.33
−$0.01 · -0.14%
Tevogen Bio Holdings Inc. is a clinical-stage biotechnology firm dedicated to developing "off-the-shelf" precision T cell therapies for conditions across virology, oncology, and neurology. Its flagship experimental product, TVGN 489, is a precision T cell therapeutic engineered to address critical unmet needs in patients with acute-risk COVID-19, alongside a specific population experiencing long COVID. The company's operations are headquartered in Warren, New Jersey.
Latest quote
$7.33
−$0.01 · -0.14%
Regular session · ET · Market data may be delayed.
Tevogen Bio Holdings Inc. is a clinical-stage biotechnology firm dedicated to developing "off-the-shelf" precision T cell therapies for conditions across virology, oncology, and neurology. Its flagship experimental product, TVGN 489, is a precision T cell therapeutic engineered to address critical unmet needs in patients with acute-risk COVID-19, alongside a specific population experiencing long COVID. The company's operations are headquartered in Warren, New Jersey.
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
60
Fair Value
Sentiment
51
Mixed
Risk
66
High Risk
Momentum
18
Strong Down
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Tevogen Bio Holdings Inc. is a clinical-stage biotechnology firm dedicated to developing "off-the-shelf" precision T cell therapies for conditions across virology, oncology, and neurology. Its flagship experimental product, TVGN 489, is a precision T cell therapeutic engineered to address critical unmet needs in patients with acute-risk COVID-19, alongside a specific population experiencing long COVID. The company's operations are headquartered in Warren, New Jersey.
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Cost of goods sold | — | 403.58K USD | 378.36K USD | — | — |
| Gross profit | — | −403.58K USD | −378.36K USD | — | — |
| Research and development | 11.11M USD | 31.03M USD | 4.4M USD | — | 2.96M USD |
| Selling, general, and administrative | 15.03M USD | 22.13M USD | 4.06M USD | 953.08K USD | 1.66M USD |
| Operating expenses | 26.14M USD | 53.16M USD | 8.46M USD | 953.08K USD | 4.62M USD |
| Interest income | — | — | — | 4.95M USD | — |
| Interest expense | 195.62K USD | 184.04K USD | 256.03K USD | — | 598.5K USD |
| Depreciation and amortization | 509.2K USD | 403.58K USD | 378.36K USD | 230.82K USD | 9.38K USD |
| Operating income | −26.14M USD | −53.56M USD | −8.84M USD | −953.08K USD | −4.62M USD |
| Net income | −26.28M USD | −10.11M USD | −60.48M USD | 4.41M USD | −15.6M USD |
Company facts updated Sep 9, 2026.
Recent quarterly results
Funds reporting this stock among their holdings, ordered by reported position size.
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
